OS Therapies Announced That The Last Patient Enrolled In AOST-2121 Clinical Trial Of OST-HER2 In Recurred, Resected Osteosarcoma Has Received Its Last Treatment Dose, Primary Endpoint Analysis Is Expected By Early In The Fourth Quarter Of 2024

This last patient is expected to complete its final radiological imaging evaluation as part of the 12-month Event Free Survival primary endpoint analysis by early in the fourth quarter of 2024. Concurrently, the Company will close all clinical trial sites and lock the database in preparation for data analysis and topline data readout that is expected to be announced in the fourth quarter of 2024.